The pathophysiology of heme in the brain

Current Alzheimer Research

Volumn 13, Issue 2, 2016, Pages 174-184

  Gozzelino, Raffaella ^a,b  

^a INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^b NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

Heme; Iron; Neurodegenerative diseases; Neuronal cytotoxicity

Indexed keywords

HEME;

ARTICLE; BRAIN; HUMAN; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROTOXICITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TRANSPORT; ANIMAL; DEGENERATIVE DISEASE; METABOLISM;

ANIMALS; BRAIN; HEME; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 84959348395     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150921103304     Document Type: Article

References (190)

1. Reedy CJ, Gibney BR. Heme protein assemblies. Chem Rev 104: 617-649 (2004).
2. Korolnek T, Hamza I. Like iron in the blood of the people: the requirement for heme trafficking in iron metabolism. Front Pharmacol 5: 126 (2014).
3. Chiabrando D, Vinchi F, Fiorito V, Mercurio S, Tolosano E. Heme in pathophysiology: a matter of scavenging, metabolism and trafficking across cell membranes. Front Pharmacol 5: 61 (2014).
4. Larsen R, Gouveia Z, Soares MP, Gozzelino R. Heme cytotoxicity and the pathogenesis of immune-mediated inflammatory diseases. Front Pharmacol 3: 77 (2012).
5. Gozzelino R, Jeney V, Soares MP. Mechanisms of cell protection by heme oxygenase-1. Ann Rev Pharmacol Toxicol 50: 323-354 (2010).
6. Ishii DN, Maniatis GM, Haemin promotes rapid neurite outgrowth in cultured mouse neuroblastoma cells. Nature 274: 372-374 (1978).
7. Kimura I, Nakayama Y, Konishi M, Kobayashi T, Mori M, Ito M, et al. Neuferricin, a novel extracellular heme-binding protein, promotes neurogenesis. J Neurochem 112: 1156-1167 (2010).
8. Kim HJ, Khalimonchuk O, Smith PM, Winge DR. Structure, function, and assembly of heme centers in mitochondrial respiratory complexes. Biochim Biophys Acta 1823: 1604-1616 (2012).
9. Smith PM, Fox JL, Winge DR, Biogenesis of the cytochrome bc(1) complex and role of assembly factors. Biochim Biophys Acta 1817: 276-286 (2012).
10. Soto IC, Fontanesi F, Liu J, Barrientos A. Biogenesis and assembly of eukaryotic cytochrome c oxidase catalytic core. Biochim Biophys Acta 1817: 883-897 (2012).
11. Boehning D, Snyder SH. Novel neural modulators. Ann Rev Neurosci 26: 105-131 (2003).
12. Ingi T, Chiang G, Ronnett GV. The regulation of heme turnover and carbon monoxide biosynthesis in cultured primary rat olfactory receptor neurons. J Neurosci 16: 5621-5628 (1996).
13. Wang X, Li J, Dong G, Yue J. The endogenous substrates of brain CYP2D. Eur J Pharmacol 724: 211-218 (2014).
14. Meyer RP, Gehlhaus M, Knoth R, Volk B. Expression and function of cytochrome p450 in brain drug metabolism. Curr Drug Metabol 8: 297-306 (2007).
15. Burmester T, Weich B, Reinhardt S, Hankeln T. A vertebrate globin expressed in the brain. Nature 407: 520-523 (2000).
16. Raychaudhuri S, Skommer J, Henty K, Birch N, Brittain T. Neuroglobin protects nerve cells from apoptosis by inhibiting the intrinsic pathway of cell death. Apoptosis 15: 401-411 (2010).
17. Heinemann IU, Jahn M, Jahn D. The biochemistry of heme biosynthesis. Arch Biochem Biophys 474: 238-251 (2008).
18. Paterniti JR Jr, Lin CI, Beattie DS. Delta-Aminolevulinic acid synthetase: regulation of activity in various tissues of the aging rat. Arch Biochem Biophys 191: 792-797 (1978).
19. Dailey HA, Dailey TA, Wu CK, Medlock AE, Wang KF, Rose JP, et al. Ferrochelatase at the millennium: structures, mechanisms and [2Fe-2S] clusters. Cellular and molecular life sciences: CMLS 57: 1909-1926 (2000).
20. Ponka P. Cell biology of heme. Am J Med Sci 318: 241-256 (1999).
21. Atamna H. Heme, iron, and the mitochondrial decay of ageing. Ageing Res Rev 3: 303-318 (2004).
22. Atamna H, Killilea DW, Killilea AN, Ames BN. Heme deficiency may be a factor in the mitochondrial and neuronal decay of aging. Proc Natl Acad Sci USA 99: 14807-14812 (2002).
23. Taketani S, Adachi Y, Nakahashi Y. Regulation of the expression of human ferrochelatase by intracellular iron levels. Eur J Biochem 267: 4685-4692 (2000).
24. Maines MD, Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 2: 2557-2568 (1988).
25. McCoubrey WK Jr, Huang TJ, Maines MD. Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. Eur J Biochem 247: 725-732 (1997).
26. Hayashi S, Omata Y, Sakamoto H, Higashimoto Y, Hara T, Sagara Y, et al. Characterization of rat heme oxygenase-3 gene. Implication of processed pseudogenes derived from heme oxygenase-2 gene. Gene 336: 241-250 (2004).
27. Maines MD, Trakshel GM, Kutty RK. Characterization of two constitutive forms of rat liver microsomal heme oxygenase. Only one molecular species of the enzyme is inducible. J BIol Chem 261: 411-419 (1986).
28. Cruse I, Maines MD. Evidence suggesting that the two forms of heme oxygenase are products of different genes. J Biol Chem 263: 3348-3353 (1988).
29. Wagener FA, Volk HD, Willis D, Abraham NG, Soares MP, Adema GJ, et al. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev 55: 551-571 (2003).
30. Scapagnini G, D’Agata V, Calabrese V, Pascale A, Colombrita C, Alkon D, et al. Gene expression profiles of heme oxygenase isoforms in the rat brain. Brain Res 954: 51-59 (2002).
31. Ewing JF, Maines MD. Rapid induction of heme oxygenase 1 mRNA and protein by hyperthermia in rat brain: heme oxygenase 2 is not a heat shock protein. Proc Natl Acad Sci USA 88: 5364-5368 (1991).
32. Parfenova H, Leffler CW. Cerebroprotective functions of HO-2. Curr Pharm Des 14: 443-453 (2008).
33. Dwyer BE, Nishimura RN, De Vellis J, Yoshida T. Heme oxygenase is a heat shock protein and PEST protein in rat astroglial cells. Glia 5: 300-305 (1992).
34. Turner CP, Bergeron M, Matz P, Zegna A, Noble LJ, Panter SS, et al. Heme oxygenase-1 is induced in glia throughout brain by subarachnoid hemoglobin. J Cereb Blood Flow Metabol 18: 257-273 (1998).
35. Tyrrell R. Redox regulation and oxidant activation of heme oxygenase-1. Free Radic Res 31: 335-340 (1999)
36. Prestera T, Talalay P, Alam J, Ahn YI, Lee PJ, Choi AM. Parallel induction of heme oxygenase-1 and chemoprotective phase 2 enzymes by electrophiles and antioxidants: regulation by upstream antioxidant-responsive elements (ARE). Mol Med 1: 827-837 (1995).
37. Elbirt KK, Bonkovsky HL. Heme oxygenase: recent advances in understanding its regulation and role. Proc Assoc Am Phys 111: 438-447 (1999).
38. Wagner KR, Sharp FR, Ardizzone TD, Lu A, Clark JF. Heme and iron metabolism: role in cerebral hemorrhage. J Cereb Blood Flow Metabol 23: 629-652 (2003).
39. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 61: 748-755 (1968).
40. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 235: 1043-1046 (1987).
41. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of hemoglobin to bilirubin. Trans Assoc Am Phys 82: 363-371 (1969).
42. Fenton HJH. Oxidation of tartaric acid in presence of iron. J Chem Soc (Lond.)-, 899-910 (1894).
43. Gozzelino R, Soares MP. Coupling heme and iron metabolism via ferritin H chain. Antioxidants Redox Signal 20: 1754-1769 (2014).
44. Andrews SC, Arosio P, Bottke W, Briat JF, von Darl M, Harrison PM, et al. Structure, function, and evolution of ferritins. J Inorg Biochem 47: 161-174 (1992).
45. Asano T, Komatsu M, Yamaguchi-Iwai Y, Ishikawa F, Mizushima N, Iwai K. Distinct mechanisms of ferritin delivery to lysosomes in iron-depleted and iron-replete cells. Mol Cell Biol 31: 2040-2052 (2011).
46. Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature 509: 105-109 (2014).
47. Lawson DM, Treffry A, Artymiuk PJ, Harrison PM, Yewdall SJ, Luzzago A, et al. Identification of the ferroxidase centre in ferritin. FEBS Lett 254: 207-210 (1989)
48. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275: 161-203 (1996).
49. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, et al. Genetic or pharmacological iron chelation prevents MPTPinduced neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron 37: 899-909 (2003)
50. Schipper HM. Heme oxygenase-1: role in brain aging and neurodegeneration. Exp Gerontol 35: 821-830 (2000)
51. Orozco-Ibarra M, Chirino YI, Pedraza-Chaverri J. Role of hemeoxygenase-1 in the neurodegenerative disorders. Rev Neurol 43: 556-562 (2006).
52. Parfenova H, Carratu P, Tcheranova D, Fedinec A, Pourcyrous M, Leffler CW. Epileptic seizures cause extended postictal cerebral vascular dysfunction that is prevented by HO-1 overexpression. American journal of physiology. Heart Circ Physiol 288: H2843-2850 (2005).
53. Carratu P, Pourcyrous M, Fedinec A, Leffler CW, Parfenova H. Endogenous heme oxygenase prevents impairment of cerebral vascular functions caused by seizures. Am J Physiol Heart and Circ Physiol 285: H1148-1157 (2003).
54. Parfenova H, Leffler CW, Basuroy S, Liu J, Fedinec AL. Antioxidant roles of heme oxygenase, carbon monoxide, and bilirubin in cerebral circulation during seizures. J Cerebral Blood Flow Metabol 32: 1024-1034 (2012).
55. Parfenova H, Basuroy S, Bhattacharya S, Tcheranova D, Qu Y, Regan RF, et al. Glutamate induces oxidative stress and apoptosis in cerebral vascular endothelial cells: contributions of HO-1 and HO-2 to cytoprotection. American journal of physiology. Cell Physiol 290: C1399-1410 (2006).
56. Basuroy S, Bhattacharya S, Tcheranova D, Qu Y, Regan RF, Leffler CW, et al. HO-2 provides endogenous protection against oxidative stress and apoptosis caused by TNF-alpha in cerebral vascular endothelial cells. Am J Physiol. Cell Physiol 291: C897-908 (2006).
57. Schipper HM. Heme oxygenase expression in human central nervous system disorders. Free Rad Biol Med 37: 1995-2011 (2004).
58. Light WR 3rd, Olson JS, Transmembrane movement of heme. J Biol Chem 265: 15623-15631 (1990).
59. Yuan X, Fleming MD, Hamza I. Heme transport and erythropoiesis. Curr Opin Chem Biol 17: 204-211 (2013).
60. Rajagopal A, Rao AU, Amigo J, Tian M, Upadhyay SK, Hall C, et al. Haem homeostasis is regulated by the conserved and concerted functions of HRG-1 proteins. Nature 453: 1127-1131 (2008).
61. Quigley JG, Burns CC, Anderson MM, Lynch ED, Sabo KM, Overbaugh J, et al. Cloning of the cellular receptor for feline leukemia virus subgroup C (FeLV-C), a retrovirus that induces red cell aplasia. Blood 95: 1093-1099 (2000).
62. Khan AA, Quigley JG. Heme and FLVCR-related transporter families SLC48 and SLC49. Mol Aspects Med 34: 669-682 (2013).
63. Shayeghi M, Latunde-Dada GO, Oakhill JS, Laftah AH, Takeuchi K, Halliday N, et al. Identification of an intestinal heme transporter. Cell 122: 789-801 (2005).
64. Yuan X, Protchenko O, Philpott CC, Hamza I. Topologically conserved residues direct heme transport in HRG-1-related proteins. J Biol Chem 287: 4914-4924 (2012).
65. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445: 168-176 (2007).
66. Duffy SP, Shing J, Saraon P, Berger LC, Eiden MV, Wilde A, et al. The Fowler syndrome-associated protein FLVCR2 is an importer of heme. Mol Cell Biol 30: 5318-5324 (2010).
67. Castro-Gago M, Alonso A, Pintos-Martinez E, Beiras-Iglesias A, Campos Y, Arenas J, et al. Congenital hydranencephalichydrocephalic syndrome associated with mitochondrial dysfunction. J Child Neurol 14: 131-135 (1999)
68. Atamna H, Liu J, Ames BN. Heme deficiency selectively interrupts assembly of mitochondrial complex IV in human fibroblasts: revelance to aging. J Biol Chem 276: 48410-48416 (2001).
69. Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 127: 917-928 (2006).
70. Andrews NC. When is a heme transporter not a heme transporter? When it’s a folate transporter. Cell Metabol 5: 5-6 (2007).
71. Gordon N. Cerebral folate deficiency. Dev Med Child Neurol 51: 180-182 (2009).
72. Latunde-Dada GO, Laftah AH, Masaratana P, McKie AT, Simpson RJ. Expression of ABCG2 (BCRP) in mouse models with enhanced erythropoiesis. Front Pharmacol 5: 135 (2014).
73. Latunde-Dada GO, Simpson RJ, McKie AT. Recent advances in mammalian haem transport. Trends Biochem Sci 31: 182-188 (2006).
74. Zeng Y, Callaghan D, Xiong H, Yang Z, Huang P, Zhang W. Abcg2 deficiency augments oxidative stress and cognitive deficits in Tg-SwDI transgenic mice. J Neurochem 122: 456-469 (2012).
75. Bhattacharya S, Das A, Mallya K, Ahmad I. Maintenance of retinal stem cells by Abcg2 is regulated by notch signaling. J Cell Sci 120: 2652-2662 (2007).
76. Rajadhyaksha AM, Elemento O, Puffenberger EG, Schierberl KC, Xiang JZ, Putorti ML, et al. Mutations in FLVCR1 cause posterior column ataxia and retinitis pigmentosa. Am J Human Genet 87: 643-654 (2010).
77. Yanatori I, Yasui Y, Miura K, Kishi F. Mutations of FLVCR1 in posterior column ataxia and retinitis pigmentosa result in the loss of heme export activity. Blood Cells Mol Dis 49: 60-66 (2012).
78. Higgins JJ, Morton DH, Patronas N, Nee LE. An autosomal recessive disorder with posterior column ataxia and retinitis pigmentosa. Neurology 49: 1717-1720 (1997).
79. Ishiura H, Fukuda Y, Mitsui J, Nakahara Y, Ahsan B, Takahashi Y, et al. Posterior column ataxia with retinitis pigmentosa in a Japanese family with a novel mutation in FLVCR1. Neurogenetics 12: 117-121 (2011).
80. Chiabrando D, Marro S, Mercurio S, Giorgi C, Petrillo S, Vinchi F, et al. The mitochondrial heme exporter FLVCR1b mediates erythroid differentiation. J Clin Invest 122: 4569-4579 (2012).
81. Vinchi F, Ingoglia G, Chiabrando D, Mercurio S, Turco E, Silengo L, et al. Heme exporter FLVCR1a regulates heme synthesis and degradation and controls activity of cytochromes P450. Gastroenterology 146: 1325-1338 (2014).
82. Fukuda K, Richmon JD, Sato M, Sharp FR, Panter SS, Noble LJ. Induction of heme oxygenase-1 (HO-1) in glia after traumatic brain injury. Brain Res 736: 68-75 (1996).
83. Panahian N, Yoshiura M, Maines MD. Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. J Neurochem 72: 1187-1203 (1999).
84. Tanaka N, Ikeda Y, Ohta Y, Deguchi K, Tian F, Shang J, et al. Expression of Keap1-Nrf2 system and antioxidative proteins in mouse brain after transient middle cerebral artery occlusion. Brain Res 1370: 246-253 (2011).
85. Tolosano E, Altruda F, Hemopexin: structure, function, and regulation. DNA Cell Biol 21: 297-306 (2002).
86. Sung L, Shibata M, Eskew JD, Shipulina N, Morales PJ, Smith A. Cell-surface events for metallothionein-1 and heme oxygenase-1 regulation by the hemopexin-heme transport system. Antioxidants Redox Signal 2: 753-765 (2000).
87. Chamoun V, Zeman A, Blennow K, Fredman P, Wallin A, Keir G, et al. Haptoglobins as markers of blood-CSF barrier dysfunction: the findings in normal CSF. J Neurol Sci 182: 117-121 (2001).
88. Spagnuolo MS, Maresca B, Mollica MP, Cavaliere G, Cefaliello C, Trinchese G, et al. Haptoglobin increases with age in rat hippocampus and modulates Apolipoprotein E mediated cholesterol trafficking in neuroblastoma cell lines. Front Cell Neurol 8: 212 (2014).
89. Johnson G, Brane D, Block W, van Kammen DP, Gurklis J, Peters JL, et al. Cerebrospinal fluid protein variations in common to Alzheimer’s disease and schizophrenia. Appl Theor Electrophor 3: 47-53 (1992).
90. Arguelles S, Venero JL, Garcia-Rodriguez S, Tomas-Camardiel M, Ayala A, Cano J, et al. Use of haptoglobin and transthyretin as potential biomarkers for the preclinical diagnosis of Parkinson’s disease. Neurochem Intern 57: 227-234 (2010).
91. Huang YC, Wu YR, Tseng MY, Chen YC, Hsieh SY, Chen CM. Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington’s disease. PloS One 6: e15809 (2011).
92. Zhao X, Song S, Sun G, Strong R, Zhang J, Grotta JC, et al. Neuroprotective role of haptoglobin after intracerebral hemorrhage. J Neurosci 29: 15819-15827 (2009).
93. Galicia G, Maes W, Verbinnen B, Kasran A, Bullens D, Arredouani M, et al. Haptoglobin deficiency facilitates the development of autoimmune inflammation. Eur J Immunol 39: 3404-3412 (2009).
94. Borsody M, Burke A, Coplin W, Miller-Lotan R, Levy A. Haptoglobin and the development of cerebral artery vasospasm after subarachnoid hemorrhage. Neurology 66: 634-640 (2006).
95. Lee MY, Kim SY, Choi JS, Lee IH, Choi YS, Jin JY, et al. Upregulation of haptoglobin in reactive astrocytes after transient forebrain ischemia in rats J Cereb Blood Flow Metab 22: 1176-1180 (2002).
96. Zhao X, Song S, Sun G, Zhang J, Strong R, Zhang L, et al. Cytoprotective role of haptoglobin in brain after experimental intracerebral hemorrhage. Acta Neurochirurg Suppl 111: 107-112 (2011).
97. Teunissen CE, van Boxtel MP, Bosma H, Bosmans E, Delanghe J, De Bruijn C, et al. Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol 134: 142-150 (2003).
98. Schaer CA, Deuel JW, Bittermann AG, Rubio IG, Schoedon G, Spahn DR, et al. Mechanisms of haptoglobin protection against hemoglobin peroxidation triggered endothelial damage. Cell Death Differ 20: 1569-1579 (2013).
99. Camborieux L, Bertrand N, Swerts JP. Changes in expression and localization of hemopexin and its transcripts in injured nervous system: a comparison of central and peripheral tissues. Neuroscience 82: 1039-1052 (1998).
100. Dong B, Cai M, Fang Z, Wei H, Zhu F, Li G, et al. Hemopexin induces neuroprotection in the rat subjected to focal cerebral ischemia. BMC Neurosci 14: 58 (2013).
101. Morello N, Bianchi FT, Marmiroli P, Tonoli E, Rodriguez Menendez V, Silengo L, et al. A role for hemopexin in oligodendrocyte differentiation and myelin formation. PloS One 6: e20173 (2011).
102. Gutteridge JM, Smith A. Antioxidant protection by haemopexin of haem-stimulated lipid peroxidation. Biochem J 256: 861-865 (1988).
103. Otterbein LE, Hedblom A, Harris C, Csizmadia E, Gallo D, Wegiel B. Heme oxygenase-1 and carbon monoxide modulate DNA repair through ataxia-telangiectasia mutated (ATM) protein. Proc Natl Acad Sci USA 108: 14491-14496 (2011).
104. Morello N, Tonoli E, Logrand F, Fiorito V, Fagoonee S, Turco E, et al. Haemopexin affects iron distribution and ferritin expression in mouse brain. J Cel Mol Med 13: 4192-4204 (2009).
105. Li RC, Saleem S, Zhen G, Cao W, Zhuang H, Lee J, et al. Hemehemopexin complex attenuates neuronal cell death and stroke damage. J Cereb Blood Metabol 29: 953-964 (2009).
106. Chen L, Zhang X, Chen-Roetling J, Regan RF. Increased striatal injury and behavioral deficits after intracerebral hemorrhage in hemopexin knockout mice. J Neurosurg 114: 1159-1167 (2011).
107. Hahl P, Davis T, Washburn C, Rogers JT, Smith A. Mechanisms of neuroprotection by hemopexin: modeling the control of heme and iron homeostasis in brain neurons in inflammatory states. J Neurochem 125: 89-101 (2013).
108. Todorich B, Pasquini JM, Garcia CI, Paez PM, Connor JR. Oligodendrocytes and myelination: the role of iron. Glia 57: 467-478 (2009).
109. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 37: 48-57 (2010).
110. Pardridge WM. Drug targeting to the brain. Pharma Res 24: 1733-1744 (2007).
111. Pardridge WM, Brain metabolism: a perspective from the bloodbrain barrier. Physiol Rev 63: 1481-1535 (1983).
112. Yan F, Wang Y, He S, Ku S, Gu W, Ye L. Transferrin-conjugated, fluorescein-loaded magnetic nanoparticles for targeted delivery across the blood-brain barrier. J Mat Sci Mater Med 24: 2371-2379 (2013).
113. Vincent SH. Oxidative effects of heme and porphyrins on proteins and lipids. Semin Hematol 26: 105-113 (1989).
114. Jeney V, Balla J, Yachie A, Varga Z, Vercellotti GM, Eaton JW, et al. Pro-oxidant and cytotoxic effects of circulating heme. Blood 100: 879-887 (2002).
115. Kumar S, Bandyopadhyay U. Free heme toxicity and its detoxification systems in human. Toxicol Lett 157: 175-188 (2005).
116. Gozzelino R, Soares MP. Heme sensitization to TNF-mediated programmed cell death. Advan Exo Med Biol 691: 211-219 (2011).
117. Gozzelino R, Soares MP, Coupling Heme and Iron Metabolism via Ferritin H Chain. Antioxidants Redox Signal 20: 1754-69 (2013).
118. Coleman M. Axon degeneration mechanisms: commonality amid diversity. Nature reviews. Neuroscience 6: 889-898 (2005).
119. Coleman MP, Perry VH. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci 25: 532-537 (2002).
120. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262: 689-695 (1993).
121. Smythies J. The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: functional interrelationships in health and disease: a review-discussion. Neurotox Res 1: 27-39 (1999).
122. Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin 30: 379-387 (2009).
123. Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D. Antioxidant therapy in acute central nervous system injury: current state. Pharmacol Rev 54: 271-284 (2002).
124. Kitagishi Y, Kobayashi M, Kikuta K, Matsuda S. Roles of PI3K/AKT/GSK3/mTOR Pathway in Cell Signaling of Mental Illnesses. Depression Res Treatment 2012: 752563 (2012).
125. Roediger B, Armati PJ. Oxidative stress induces axonal beading in cultured human brain tissue. Neurobiol Dis 13: 222-229 (2003).
126. Velez-Pardo C, Jimenez Del Rio M, Verschueren H, Ebinger G, Vauquelin G, Dopamine and iron induce apoptosis in PC12 cells. Pharmacol Toxicol 80: 76-84 (1997).
127. Elseweidy MM, Abd El-Baky AE. Effect of dietary iron overload in rat brain: oxidative stress, neurotransmitter level and serum metal ion in relation to neurodegenerative disorders. Ind J Exp Biol 46: 855-858 (2008).
128. Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, Horwitz J, et al. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc Natl Acad Sci USA 95: 7659-7663 (1998).
129. Kuhn DM, Sakowski SA, Sadidi M, Geddes TJ. Nitrotyrosine as a marker for peroxynitrite-induced neurotoxicity: the beginning or the end of the end of dopamine neurons? J Neurochem 89: 529-536 (2004).
130. Su KG, Banker G, Bourdette D, Forte M. Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr Neurol Neurosci Rep 9: 411-417 (2009).
131. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 9: 69-92 (1999).
132. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, et al. Inflammatory cortical demyelination in early multiple sclerosis. New Eng J Med 365: 2188-2197 (2011).
133. Urrutia P, Aguirre P, Esparza A, Tapia V, Mena NP, Arredondo M, et al. Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells. J Neurochem 126: 541-549 (2013).
134. Urrutia PJ, Mena NP, Nunez MT. The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders. Front Pharmacol 5: 38 (2014).
135. Li L, Holscher C, Chen BB, Zhang ZF, Liu YZ. Hepcidin treatment modulates the expression of divalent metal transporter-1, ceruloplasmin, and ferroportin-1 in the rat cerebral cortex and hippocampus. Biol Trace Element Res 143: 1581-1593 (2011).
136. Pinto JP, Arezes J, Dias V, Oliveira S, Vieira I, Costa M, et al. Physiological implications of NTBI uptake by T lymphocytes. Front Pharmacol 5: 24 (2014).
137. Daneman R. The blood-brain barrier in health and disease. Ann Neurol 72: 648-672 (2012).
138. Mitchell K, Yang HY, Berk JD, Tran JH, Iadarola MJ. Monocyte chemoattractant protein-1 in the choroid plexus: a potential link between vascular pro-inflammatory mediators and the CNS during peripheral tissue inflammation. Neuroscience 158: 885-895 (2009).
139. Axtell RC, Steinman L. Gaining entry to an uninflamed brain. Nat Immunol 10: 453-455 (2009).
140. Meeker RB, Williams K, Killebrew DA, Hudson LC. Cell trafficking through the choroid plexus. Cell Adhes Migr 6: 390-396 (2012).
141. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest 120: 1368-1379 (2010).
142. Zhang Z, Zhang ZY, Wu Y, Schluesener HJ. Lesional accumulation of CD163+ macrophages/microglia in rat traumatic brain injury. Brain Res 1461: 102-110 (2012).
143. Cabantchik ZI, Munnich A, Youdim MB, Devos D. Regional siderosis: a new challenge for iron chelation therapy. Front Pharmacol 4: 167 (2013).
144. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 2: 1219-1220 (1987)
145. Rouault TA. Iron metabolism in the CNS: implications for neurodegenerative diseases. Nature reviews. Neuroscience 14: 551-564 (2013).
146. Barone E, Di Domenico F, Mancuso C, Butterfield DA. The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it’s time for reconciliation. Neurobiol Dis 62: 144-159 (2014).
147. Ham D, Schipper HM. Heme oxygenase-1 induction and mitochondrial iron sequestration in astroglia exposed to amyloid peptides. Cell Mol Biol 46: 587-596 (2000).
148. Zeynalov E, Dore S. Low doses of carbon monoxide protect against experimental focal brain ischemia. Neurotox Res 15: 133-137 (2009).
149. Queiroga CS, Vercelli A, Vieira HL. Carbon monoxide and the CNS: challenges and achievements. Brit J Pharmacol 172: 1533-1545 (2015).
150. Isaya G. Mitochondrial iron-sulfur cluster dysfunction in neurodegenerative disease. Front Pharmacol 5: 29 (2014).
151. Schipper HM, Brain iron deposition and the free radicalmitochondrial theory of ageing. Ageing Res Rev 3: 265-301 (2004).
152. Wong BX, Duce JA. The iron regulatory capability of the major protein participants in prevalent neurodegenerative disorders. Front Pharmacol 5: 81 (2014).
153. Ono T, Cutler RG. Age-dependent relaxation of gene repression: increase of endogenous murine leukemia virus-related and globinrelated RNA in brain and liver of mice. Proc Natl Acad Sci USA 75: 4431-4435 (1978).
154. Wu CW, Liao PC, Yu L, Wang ST, Chen ST, Wu CM, et al. Hemoglobin promotes Abeta oligomer formation and localizes in neurons and amyloid deposits. Neurobiol Dis 17: 367-377 (2004).
155. Zlokovic BV, Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci 28: 202-208 (2005).
156. Richter F, Meurers BH, Zhu C, Medvedeva VP, Chesselet MF. Neurons express hemoglobin alpha-and beta-chains in rat and human brains. J Comp Neurol 515: 538-547 (2009).
157. de la Torre JC. Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3: 184-190 (2004).
158. Jellinger KA, Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109: 813-836 (2002).
159. Buee L, Hof PR, Delacourte A. Brain microvascular changes in Alzheimer’s disease and other dementias. Ann NY Acad Sci 826: 7-24 (1997).
160. Poon HF, Calabrese V, Scapagnini G, Butterfield DA. Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J Gerontol Seri A Biol Sci Med Sci 59: 478-493 (2004).
161. Barone E, Di Domenico F, Sultana R, Coccia R, Mancuso C, Perluigi M, et al. Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med 52: 2292-2301 (2012).
162. Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70: 532-540 (2011).
163. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539 (2002).
164. Atamna H, Frey WH 2nd. A role for heme in Alzheimer’s disease: heme binds amyloid beta and has altered metabolism. Proc Natl Acad Sci USA 101: 11153-11158 (2004).
165. Chuang JY, Lee CW, Shih YH, Yang T, Yu L, Kuo YM. Interactions between amyloid-beta and hemoglobin: implications for amyloid plaque formation in Alzheimer’s disease. PloS One 7: e33120 (2012).
166. Stone J. What initiates the formation of senile plaques? The origin of Alzheimer-like dementias in capillary haemorrhages. Med Hypotheses 71: 347-359 (2008).
167. Oyama R, Yamamoto H, Titani K. Glutamine synthetase, hemoglobin alpha-chain, and macrophage migration inhibitory factor binding to amyloid beta-protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer’s disease brain by immunoprecipitation. Biochim Biophys Acta 1479: 91-102 (2000).
168. Ayuso P, Martinez C, Lorenzo-Betancor O, Pastor P, Luengo A, Jimenez-Jimenez FJ, et al. A polymorphism located at an ATG transcription start site of the heme oxygenase-2 gene is associated with classical Parkinson’s disease. Pharmacogen Genom 21: 565-571 (2011).
169. Ayuso P, Martinez C, Pastor P, Lorenzo-Betancor O, Luengo A, Jimenez-Jimenez FJ, et al. An association study between Heme oxygenase-1 genetic variants and Parkinson’s disease. Front Cell Neurosci 8: 298 (2014).
170. Schipper HM, Song W, Zukor H JR. Hascalovici, D. Zeligman, Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. J Neurochem 110: 469-485 (2009).
171. Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, de Klerk O, et al. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA. J Neural Transm 115: 1001-1009 (2008).
172. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson’s disease. Science 302: 819-822 (2003).
173. Bendor JT, Logan TP, Edwards RH. The function of alphasynuclein. Neuron 79: 1044-1066 (2013).
174. Trojanowski JQ, Goedert M, Iwatsubo T, Lee VM. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson’s disease and Lewy body dementia. Cell Death Diff 5: 832-837 (1998).
175. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, et al. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10: 717-721 (1999).
176. Davies P, Moualla D, Brown DR. Alpha-synuclein is a cellular ferrireductase. PloS One 6: e15814 (2011).
177. Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, et al. GATA transcription factors directly regulate the Parkinson’s disease-linked gene alpha-synuclein. Proc Natl Acad Sci USA 105: 10907-10912 (2008).
178. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, et al. Red blood cells are the major source of alpha-synuclein in blood. Neuro-degenerative Dis 5: 55-59 (2008).
179. Gerlach M, Double KL, Youdim MB, Riederer P. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm 70: 133-142 (2006).
180. Foulds PG, Diggle P, Mitchell JD, Parker A, Hasegawa M, Masuda-Suzukake M, et al. A longitudinal study on alphasynuclein in blood plasma as a biomarker for Parkinson’s disease. Sci Rep 3: 2540 (2013).
181. Shergill JK, Cammack R, Cooper CE, Cooper JM, Mann VM, Schapira AH. Detection of nitrosyl complexes in human substantia nigra, in relation to Parkinson’s disease. Biochem Biophys Res Commun 228: 298-305 (1996).
182. Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, Rane A, et al. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J Neursosci 27: 13997-14006 (2007).
183. Abbott RD, Ross GW, Tanner CM, Andersen JK, Masaki KH, Rodriguez BL, et al. Late-life hemoglobin and the incidence of Parkinson’s disease. Neurobiol Aging 33: 914-920 (2012).
184. Ehrenreich H, Aust C, Krampe H, Jahn H, Jacob S, Herrmann M, et al. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metabolic Brain Dis 19: 195-206 (2004).
185. Punnonen J, Miller JL, Collier TJ, Spencer JR, Agonists of the tissue-protective erythropoietin receptor in the treatment of Parkinson’s disease. Curr Top Med Chem 15: 955-969 (2015).
186. Martins F, Catarino C, Rocha-Pereira P, Reis F, Sameiro-Faria M, Miranda V, et al. Haptoglobin 2-2 phenotype is associated with decreased serum iron levels in endstage renal disease patients resistant to rhEPO therapy. Br J Biomed Sci 71: 79-81 (2014).
187. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 129: 526-529 (2008).
188. Costa-Mallen P, Checkoway H, Zabeti A, Edenfield MJ, Swanson PD, Longstreth WT Jr, et al. The functional polymorphism of the hemoglobin-binding protein haptoglobin influences susceptibility to idiopathic Parkinson’s disease. Am J Med Genet Part B Neuropsychiatr Genet 147B: 216-222 (2008).
189. Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO, et al. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Cir Res 94: 119-126 (2004).
190. Rolla S, Ingoglia G, Bardina V, Silengo L, Altruda F, Novelli F, et al. Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development. J Immunol 191: 5451-5459 (2013).